Get started
Author

Robert Lawrence Reid

Observed names: Robert L. Reid, Robert Reid
ORCID: 0009-0008-6890-6833
Observed ORCID: 0009-0008-6890-6833
OpenAlex ID: A5069021909
Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.
2021 · Tomasz M. Beer, Charles H. McDonnell, et al. · Journal of Clinical Oncology · 28
A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.
2021 · Tomasz M. Beer, Charles H. McDonnell, et al. · Journal of Clinical Oncology · 15
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma
2008 · Dennis L. Carter, Lina Asmar, et al. · Investigational New Drugs · 13
Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
2025 · Catherine R. Marinac, Charles H. McDonnell, et al. · Cancer Prevention Research · 5
PDF
Real-world progression-free and overall survival for patients with advanced ovarian cancer utilizing PARP inhibitor second-line maintenance therapy vs active surveillance.
2022 · Robert Lawrence Reid, Junxin Shi, et al. · Journal of Clinical Oncology · 4
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.
2023 · Eric A. Klein, Charles H. McDonnell, et al. · Journal of Clinical Oncology · 3
The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
2023 · Robert Lawrence Reid, Joseph Dye, et al. · Journal of Clinical Oncology · 2
Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer.
2021 · Robert Lawrence Reid, Yiqiong Xie, et al. · Journal of Clinical Oncology · 1
Inherited germline mutations in men with prostate cancer.
2018 · Robert Reid, Marcie DiGiovanni, et al. · Journal of Clinical Oncology · 1
Rwd54 Evolution of Homologous Recombination Repair (hrr) Genetic Testing by Race Among Patients With Metastatic Prostate Cancer (mpc) in a Large Community Oncology Setting in the Us, 2015-2024
2026 · Helen Latimer, Zhaohui Su, et al. · Value in Health
Validation of a treatment-based algorithm to infer biomarker status in real-world data.
2026 · Cherrishe Brown-Bickerstaff, Saamir Pasha, et al. · Journal of Clinical Oncology
Diagnostic efficiency in precision oncology: Quantifying time to treatment initiation for biomarker-positive vs biomarker-negative metastatic NSCLC.
2026 · Zhaohui Su, Karen Todoroff, et al. · Journal of Clinical Oncology
Real-world (rw) study of the treatment journey following antibody-drug conjugate (ADC) initiation and overall survival (OS) in breast cancer (BC) in a US community setting.
2026 · Changxia Shao, Alisha Monnette Kimble, et al. · Journal of Clinical Oncology
Early-onset gastrointestinal cancers: Racial disparities in stage and survival from large-scale community oncology data.
2026 · Saamir Pasha, Jinhong Guo, et al. · Journal of Clinical Oncology
PDF
Racial variation in pain medication prescriptions among breast, prostate, and pancreatic cancer patients treated in a large community oncology setting.
2026 · Ila Sruti, Zhaohui Su, et al. · Journal of Clinical Oncology
RWD148 Real-World Associations Between Smoking Status and Genetic Driver Mutations in Metastatic Lung Cancer in US Community Oncology
2025 · Lisa Herms, Matthew Whitesell, et al. · Value in Health
Real-world duration of therapy with erythropoietic stimulating agents is predictive of overall survival in Myelodysplastic Syndromes (MDS)
2025 · Robert Reid, Rosa Banuelos, et al. · Blood
Supplementary Figure S2 from Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
2025 · Catherine R. Marinac, Charles H. McDonnell, et al.
PDF
Supplementary Table S1 from Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
2025 · Catherine R. Marinac, Charles H. McDonnell, et al.
PDF
Supplementary Figure S1 from Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
2025 · Catherine R. Marinac, Charles H. McDonnell, et al.
PDF
Data from Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
2025 · Catherine R. Marinac, Charles H. McDonnell, et al.
RWD72 Utilizing NLP to Enhance EHR Data Abstraction Accuracy in Waldenström Macroglobulinemia
2025 · Alisha Monnette, Robert Reid, et al. · Value in Health
RWD17 Evolving Real-world Trends in Biomarker Testing for Bladder Cancer: A Comprehensive Retrospective Analysis from the US Community Oncology Setting (2015-2024)
2025 · Lisa Herms, Helen Latimer, et al. · Value in Health
Descriptive epidemiology of Waldenström macroglobulinemia (WM): Demographics, outcomes, and predictors of survival in the US community oncology setting.
2025 · Alisha Monnette Kimble, Nicholas J. Robert, et al. · Journal of Clinical Oncology
PDF
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.
2024 · Donald Patrick, Melissa Ross, et al. · Journal of Clinical Oncology
PDF
Works count: 29
Citation count: 72
H-index: 4
I10-index: 3
Year
Topic
Type